A project from the American Society of Retina SpecialistsSign in to view content
APX3330, an Oral Drug in Trial for DR and DME, Demonstrated a Favorable Safety and Tolerability Profile in Multiple Phase 1 and 2 Studies
- Video
- Published 2021
Related
Category: Diabetic Retinopathy